Product Description
Clofarabine is used to treat acute lymphoblastic leukemia (ALL; a type of cancer of the white blood cells) in children and young adults 1 to 21 years old who have already received at least two other treatments. Clofarabine is in a class of medications called purine nucleoside antimetabolites. It works by killing existing cancer cells and limiting the development of new cancer cells. (Sourced from: https://medlineplus.gov/druginfo/meds/a607012.html)
Mechanisms of Action: Apoptosis Stimulant
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Ireland | Israel | Italy | Japan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Netherlands | New Zealand | Norway | Peru | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China, United States
Active Clinical Trial Count: 6
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Acute Lymphoid Leukemia|Acute Myeloid Leukemia|Acute Promyelocytic Leukemia|Anemia, Refractory, with Excess of Blasts|Biphenotypic Acute Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| GIMEMA Study LAL1509 | P2 |
Completed |
Acute Lymphoid Leukemia |
2024-12-31 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
| CTR20171404 | P2 |
Active, not recruiting |
Acute Lymphoid Leukemia |
None |
2025-04-29 |
Patient Enrollment|Treatments |
|
| CTR20171407 | P2 |
Recruiting |
Acute Lymphoid Leukemia |
None |
2025-04-29 |
Patient Enrollment|Treatments|Trial Status |
|
| TOT17 | P3 |
Active, not recruiting |
Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia |
2026-09-30 |
27% |
2024-11-27 |
Primary Endpoints|Treatments |
| HOVON 102 AML / SAKK 30/09 | P3 |
Completed |
Anemia, Refractory, with Excess of Blasts|Acute Promyelocytic Leukemia|Biphenotypic Acute Leukemia|Acute Myeloid Leukemia |
2023-09-28 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
| CTR20132344 | P3 |
Recruiting |
Unknown |
None |
2025-04-29 |